

Global Dual GLP-1R/GIPR Receptor Agonist Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/GF3A0C6BDD25EN.html>

Date: February 2026

Pages: 93

Price: US\$ 3,480.00 (Single User License)

ID: GF3A0C6BDD25EN

Abstracts

According to our (Global Info Research) latest study, the global Dual GLP-1R/GIPR Receptor Agonist market size was valued at US\$ 31519 million in 2025 and is forecast to a readjusted size of US\$ 65873 million by 2032 with a CAGR of 11.0% during review period.

In 2025, global Dual GLP-1R/GIPR Receptor Agonist production reached approximately 161.44 M Units, with an average global market price of around 189.74 USD per Unit.

A Dual GLP-1R/GIPR Receptor Agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity. To date, Tirzepatide is the only commercially available Dual GLP-1R/GIPR Receptor Agonist product in the world.

Dual GLP-1R/GIPR Receptor Agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs

and carefully tuned receptor balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven by unprecedented demand for effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma's most strategically important therapeutic area.

The upstream raw materials for Dual GLP-1R/GIPR Receptor Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.

The single-line production capacity of Dual GLP-1R/GIPR Receptor Agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.

This report is a detailed and comprehensive analysis for global Dual GLP-1R/GIPR Receptor Agonist market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Dual GLP-1R/GIPR Receptor Agonist market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global Dual GLP-1R/GIPR Receptor Agonist market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global Dual GLP-1R/GIPR Receptor Agonist market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global Dual GLP-1R/GIPR Receptor Agonist market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2021-2026

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Dual GLP-1R/GIPR Receptor Agonist

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Dual GLP-1R/GIPR Receptor Agonist market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Roche, Viking Therapeutics, Ascleptis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Dual GLP-1R/GIPR Receptor Agonist market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Injection

Oral Administration

Market segment by Receptor Agonist Properties

Balanced

Biased

Market segment by Medicinal Efficacy

Long-acting

Short-acting

Market segment by Application

Diabetes

Obesity

Others

Major players covered

Eli Lilly

Roche

Viking Therapeutics

Asclepis Pharma

Jiangsu Hengrui Medicine

East China Pharmaceutical

Tonghua Dongbao Pharmaceutical

Lepu Medical Technology

Hansoh Pharma

Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Dual GLP-1R/GIPR Receptor Agonist product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Dual GLP-1R/GIPR Receptor Agonist, with price, sales quantity, revenue, and global market share of Dual GLP-1R/GIPR Receptor Agonist from 2021 to 2026.

Chapter 3, the Dual GLP-1R/GIPR Receptor Agonist competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Dual GLP-1R/GIPR Receptor Agonist breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026. and Dual GLP-1R/GIPR Receptor Agonist market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces

analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Dual GLP-1R/GIPR Receptor Agonist.

Chapter 14 and 15, to describe Dual GLP-1R/GIPR Receptor Agonist sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Market Analysis by Type

1.3.1 Overview: Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Type: 2021 Versus 2025 Versus 2032

1.3.2 Injection

1.3.3 Oral Administration

1.4 Market Analysis by Receptor Agonist Properties

1.4.1 Overview: Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Receptor Agonist Properties: 2021 Versus 2025 Versus 2032

1.4.2 Balanced

1.4.3 Biased

1.5 Market Analysis by Medicinal Efficacy

1.5.1 Overview: Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Medicinal Efficacy: 2021 Versus 2025 Versus 2032

1.5.2 Long-acting

1.5.3 Short-acting

1.6 Market Analysis by Application

1.6.1 Overview: Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Application: 2021 Versus 2025 Versus 2032

1.6.2 Diabetes

1.6.3 Obesity

1.6.4 Others

1.7 Global GLP-1/GIPR Dual Peptide Agonist Market Size & Forecast

1.7.1 Global GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021 & 2025 & 2032)

1.7.2 Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity (2021-2032)

1.7.3 Global GLP-1/GIPR Dual Peptide Agonist Average Price (2021-2032)

2 MANUFACTURERS PROFILES

2.1 Eli Lilly

2.1.1 Eli Lilly Details

2.1.2 Eli Lilly Major Business

2.1.3 Eli Lilly GLP-1/GIPR Dual Peptide Agonist Product and Services

2.1.4 Eli Lilly GLP-1/GIPR Dual Peptide Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.1.5 Eli Lilly Recent Developments/Updates

2.2 Roche

2.2.1 Roche Details

2.2.2 Roche Major Business

2.2.3 Roche GLP-1/GIPR Dual Peptide Agonist Product and Services

2.2.4 Roche GLP-1/GIPR Dual Peptide Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.2.5 Roche Recent Developments/Updates

2.3 Viking Therapeutics

2.3.1 Viking Therapeutics Details

2.3.2 Viking Therapeutics Major Business

2.3.3 Viking Therapeutics GLP-1/GIPR Dual Peptide Agonist Product and Services

2.3.4 Viking Therapeutics GLP-1/GIPR Dual Peptide Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.3.5 Viking Therapeutics Recent Developments/Updates

2.4 Asclepis Pharma

2.4.1 Asclepis Pharma Details

2.4.2 Asclepis Pharma Major Business

2.4.3 Asclepis Pharma GLP-1/GIPR Dual Peptide Agonist Product and Services

2.4.4 Asclepis Pharma GLP-1/GIPR Dual Peptide Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.4.5 Asclepis Pharma Recent Developments/Updates

2.5 Jiangsu Hengrui Medicine

2.5.1 Jiangsu Hengrui Medicine Details

2.5.2 Jiangsu Hengrui Medicine Major Business

2.5.3 Jiangsu Hengrui Medicine GLP-1/GIPR Dual Peptide Agonist Product and Services

2.5.4 Jiangsu Hengrui Medicine GLP-1/GIPR Dual Peptide Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.5.5 Jiangsu Hengrui Medicine Recent Developments/Updates

2.6 East China Pharmaceutical

2.6.1 East China Pharmaceutical Details

2.6.2 East China Pharmaceutical Major Business

2.6.3 East China Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Product and Services

2.6.4 East China Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

- 2.6.5 East China Pharmaceutical Recent Developments/Updates
- 2.7 Tonghua Dongbao Pharmaceutical
 - 2.7.1 Tonghua Dongbao Pharmaceutical Details
 - 2.7.2 Tonghua Dongbao Pharmaceutical Major Business
 - 2.7.3 Tonghua Dongbao Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Product and Services
 - 2.7.4 Tonghua Dongbao Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
 - 2.7.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates
- 2.8 Lepu Medical Technology
 - 2.8.1 Lepu Medical Technology Details
 - 2.8.2 Lepu Medical Technology Major Business
 - 2.8.3 Lepu Medical Technology GLP-1/GIPR Dual Peptide Agonist Product and Services
 - 2.8.4 Lepu Medical Technology GLP-1/GIPR Dual Peptide Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
 - 2.8.5 Lepu Medical Technology Recent Developments/Updates
- 2.9 Hansoh Pharma
 - 2.9.1 Hansoh Pharma Details
 - 2.9.2 Hansoh Pharma Major Business
 - 2.9.3 Hansoh Pharma GLP-1/GIPR Dual Peptide Agonist Product and Services
 - 2.9.4 Hansoh Pharma GLP-1/GIPR Dual Peptide Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
 - 2.9.5 Hansoh Pharma Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: GLP-1/GIPR DUAL PEPTIDE AGONIST BY MANUFACTURER

- 3.1 Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global GLP-1/GIPR Dual Peptide Agonist Revenue by Manufacturer (2021-2026)
- 3.3 Global GLP-1/GIPR Dual Peptide Agonist Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
 - 3.4.1 Producer Shipments of GLP-1/GIPR Dual Peptide Agonist by Manufacturer Revenue (\$MM) and Market Share (%): 2025
 - 3.4.2 Top 3 GLP-1/GIPR Dual Peptide Agonist Manufacturer Market Share in 2025
 - 3.4.3 Top 6 GLP-1/GIPR Dual Peptide Agonist Manufacturer Market Share in 2025
- 3.5 GLP-1/GIPR Dual Peptide Agonist Market: Overall Company Footprint Analysis

- 3.5.1 GLP-1/GIPR Dual Peptide Agonist Market: Region Footprint
- 3.5.2 GLP-1/GIPR Dual Peptide Agonist Market: Company Product Type Footprint
- 3.5.3 GLP-1/GIPR Dual Peptide Agonist Market: Company Product Application

Footprint

- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

- 4.1 Global GLP-1/GIPR Dual Peptide Agonist Market Size by Region
 - 4.1.1 Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Region (2021-2032)
 - 4.1.2 Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Region (2021-2032)
 - 4.1.3 Global GLP-1/GIPR Dual Peptide Agonist Average Price by Region (2021-2032)
- 4.2 North America GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032)
- 4.3 Europe GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032)
- 4.4 Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032)
- 4.5 South America GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032)
- 4.6 Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Consumption Value (2021-2032)

5 MARKET SEGMENT BY TYPE

- 5.1 Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2021-2032)
- 5.2 Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Type (2021-2032)
- 5.3 Global GLP-1/GIPR Dual Peptide Agonist Average Price by Type (2021-2032)

6 MARKET SEGMENT BY APPLICATION

- 6.1 Global GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2021-2032)
- 6.2 Global GLP-1/GIPR Dual Peptide Agonist Consumption Value by Application (2021-2032)
- 6.3 Global GLP-1/GIPR Dual Peptide Agonist Average Price by Application (2021-2032)

7 NORTH AMERICA

- 7.1 North America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2021-2032)

7.2 North America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2021-2032)

7.3 North America GLP-1/GIPR Dual Peptide Agonist Market Size by Country

7.3.1 North America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Country (2021-2032)

7.3.2 North America GLP-1/GIPR Dual Peptide Agonist Consumption Value by Country (2021-2032)

7.3.3 United States Market Size and Forecast (2021-2032)

7.3.4 Canada Market Size and Forecast (2021-2032)

7.3.5 Mexico Market Size and Forecast (2021-2032)

8 EUROPE

8.1 Europe GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2021-2032)

8.2 Europe GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2021-2032)

8.3 Europe GLP-1/GIPR Dual Peptide Agonist Market Size by Country

8.3.1 Europe GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Country (2021-2032)

8.3.2 Europe GLP-1/GIPR Dual Peptide Agonist Consumption Value by Country (2021-2032)

8.3.3 Germany Market Size and Forecast (2021-2032)

8.3.4 France Market Size and Forecast (2021-2032)

8.3.5 United Kingdom Market Size and Forecast (2021-2032)

8.3.6 Russia Market Size and Forecast (2021-2032)

8.3.7 Italy Market Size and Forecast (2021-2032)

9 ASIA-PACIFIC

9.1 Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2021-2032)

9.2 Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2021-2032)

9.3 Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Market Size by Region

9.3.1 Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Region (2021-2032)

9.3.2 Asia-Pacific GLP-1/GIPR Dual Peptide Agonist Consumption Value by Region (2021-2032)

9.3.3 China Market Size and Forecast (2021-2032)

9.3.4 Japan Market Size and Forecast (2021-2032)

- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 SOUTH AMERICA

- 10.1 South America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2021-2032)
- 10.2 South America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2021-2032)
- 10.3 South America GLP-1/GIPR Dual Peptide Agonist Market Size by Country
 - 10.3.1 South America GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Country (2021-2032)
 - 10.3.2 South America GLP-1/GIPR Dual Peptide Agonist Consumption Value by Country (2021-2032)
 - 10.3.3 Brazil Market Size and Forecast (2021-2032)
 - 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 MIDDLE EAST & AFRICA

- 11.1 Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Market Size by Country
 - 11.3.1 Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Sales Quantity by Country (2021-2032)
 - 11.3.2 Middle East & Africa GLP-1/GIPR Dual Peptide Agonist Consumption Value by Country (2021-2032)
 - 11.3.3 Turkey Market Size and Forecast (2021-2032)
 - 11.3.4 Egypt Market Size and Forecast (2021-2032)
 - 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
 - 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 MARKET DYNAMICS

- 12.1 GLP-1/GIPR Dual Peptide Agonist Market Drivers
- 12.2 GLP-1/GIPR Dual Peptide Agonist Market Restraints

12.3 GLP-1/GIPR Dual Peptide Agonist Trends Analysis

12.4 Porters Five Forces Analysis

12.4.1 Threat of New Entrants

12.4.2 Bargaining Power of Suppliers

12.4.3 Bargaining Power of Buyers

12.4.4 Threat of Substitutes

12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of GLP-1/GIPR Dual Peptide Agonist and Key Manufacturers

13.2 Manufacturing Costs Percentage of GLP-1/GIPR Dual Peptide Agonist

13.3 GLP-1/GIPR Dual Peptide Agonist Production Process

13.4 Industry Value Chain Analysis

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel

14.1.1 Direct to End-User

14.1.2 Distributors

14.2 GLP-1/GIPR Dual Peptide Agonist Typical Distributors

14.3 GLP-1/GIPR Dual Peptide Agonist Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Receptor Agonist Properties, (USD Million), 2021 & 2025 & 2032

Table 3. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Medicinal Efficacy, (USD Million), 2021 & 2025 & 2032

Table 4. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 5. Eli Lilly Basic Information, Manufacturing Base and Competitors

Table 6. Eli Lilly Major Business

Table 7. Eli Lilly Dual GLP-1R/GIPR Receptor Agonist Product and Services

Table 8. Eli Lilly Dual GLP-1R/GIPR Receptor Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 9. Eli Lilly Recent Developments/Updates

Table 10. Roche Basic Information, Manufacturing Base and Competitors

Table 11. Roche Major Business

Table 12. Roche Dual GLP-1R/GIPR Receptor Agonist Product and Services

Table 13. Roche Dual GLP-1R/GIPR Receptor Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 14. Roche Recent Developments/Updates

Table 15. Viking Therapeutics Basic Information, Manufacturing Base and Competitors

Table 16. Viking Therapeutics Major Business

Table 17. Viking Therapeutics Dual GLP-1R/GIPR Receptor Agonist Product and Services

Table 18. Viking Therapeutics Dual GLP-1R/GIPR Receptor Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 19. Viking Therapeutics Recent Developments/Updates

Table 20. Asclepis Pharma Basic Information, Manufacturing Base and Competitors

Table 21. Asclepis Pharma Major Business

Table 22. Asclepis Pharma Dual GLP-1R/GIPR Receptor Agonist Product and Services

Table 23. Asclepis Pharma Dual GLP-1R/GIPR Receptor Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market

Share (2021-2026)

Table 24. Ascleitis Pharma Recent Developments/Updates

Table 25. Jiangsu Hengrui Medicine Basic Information, Manufacturing Base and Competitors

Table 26. Jiangsu Hengrui Medicine Major Business

Table 27. Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Receptor Agonist Product and Services

Table 28. Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Receptor Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 29. Jiangsu Hengrui Medicine Recent Developments/Updates

Table 30. East China Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 31. East China Pharmaceutical Major Business

Table 32. East China Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Product and Services

Table 33. East China Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 34. East China Pharmaceutical Recent Developments/Updates

Table 35. Tonghua Dongbao Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 36. Tonghua Dongbao Pharmaceutical Major Business

Table 37. Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Product and Services

Table 38. Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Receptor Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 39. Tonghua Dongbao Pharmaceutical Recent Developments/Updates

Table 40. Lepu Medical Technology Basic Information, Manufacturing Base and Competitors

Table 41. Lepu Medical Technology Major Business

Table 42. Lepu Medical Technology Dual GLP-1R/GIPR Receptor Agonist Product and Services

Table 43. Lepu Medical Technology Dual GLP-1R/GIPR Receptor Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 44. Lepu Medical Technology Recent Developments/Updates

Table 45. Hansoh Pharma Basic Information, Manufacturing Base and Competitors

- Table 46. Hansoh Pharma Major Business
- Table 47. Hansoh Pharma Dual GLP-1R/GIPR Receptor Agonist Product and Services
- Table 48. Hansoh Pharma Dual GLP-1R/GIPR Receptor Agonist Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 49. Hansoh Pharma Recent Developments/Updates
- Table 50. Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Manufacturer (2021-2026) & (K Units)
- Table 51. Global Dual GLP-1R/GIPR Receptor Agonist Revenue by Manufacturer (2021-2026) & (USD Million)
- Table 52. Global Dual GLP-1R/GIPR Receptor Agonist Average Price by Manufacturer (2021-2026) & (US\$/Unit)
- Table 53. Market Position of Manufacturers in Dual GLP-1R/GIPR Receptor Agonist, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
- Table 54. Head Office and Dual GLP-1R/GIPR Receptor Agonist Production Site of Key Manufacturer
- Table 55. Dual GLP-1R/GIPR Receptor Agonist Market: Company Product Type Footprint
- Table 56. Dual GLP-1R/GIPR Receptor Agonist Market: Company Product Application Footprint
- Table 57. Dual GLP-1R/GIPR Receptor Agonist New Market Entrants and Barriers to Market Entry
- Table 58. Dual GLP-1R/GIPR Receptor Agonist Mergers, Acquisition, Agreements, and Collaborations
- Table 59. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
- Table 60. Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Region (2021-2026) & (K Units)
- Table 61. Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Region (2027-2032) & (K Units)
- Table 62. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Region (2021-2026) & (USD Million)
- Table 63. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Region (2027-2032) & (USD Million)
- Table 64. Global Dual GLP-1R/GIPR Receptor Agonist Average Price by Region (2021-2026) & (US\$/Unit)
- Table 65. Global Dual GLP-1R/GIPR Receptor Agonist Average Price by Region (2027-2032) & (US\$/Unit)
- Table 66. Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type

(2021-2026) & (K Units)

Table 67. Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2027-2032) & (K Units)

Table 68. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Type (2021-2026) & (USD Million)

Table 69. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Type (2027-2032) & (USD Million)

Table 70. Global Dual GLP-1R/GIPR Receptor Agonist Average Price by Type (2021-2026) & (US\$/Unit)

Table 71. Global Dual GLP-1R/GIPR Receptor Agonist Average Price by Type (2027-2032) & (US\$/Unit)

Table 72. Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2021-2026) & (K Units)

Table 73. Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2027-2032) & (K Units)

Table 74. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Application (2021-2026) & (USD Million)

Table 75. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Application (2027-2032) & (USD Million)

Table 76. Global Dual GLP-1R/GIPR Receptor Agonist Average Price by Application (2021-2026) & (US\$/Unit)

Table 77. Global Dual GLP-1R/GIPR Receptor Agonist Average Price by Application (2027-2032) & (US\$/Unit)

Table 78. North America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2021-2026) & (K Units)

Table 79. North America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2027-2032) & (K Units)

Table 80. North America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2021-2026) & (K Units)

Table 81. North America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2027-2032) & (K Units)

Table 82. North America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Country (2021-2026) & (K Units)

Table 83. North America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Country (2027-2032) & (K Units)

Table 84. North America Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Country (2021-2026) & (USD Million)

Table 85. North America Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Country (2027-2032) & (USD Million)

Table 86. Europe Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2021-2026) & (K Units)

Table 87. Europe Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2027-2032) & (K Units)

Table 88. Europe Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2021-2026) & (K Units)

Table 89. Europe Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2027-2032) & (K Units)

Table 90. Europe Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Country (2021-2026) & (K Units)

Table 91. Europe Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Country (2027-2032) & (K Units)

Table 92. Europe Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Country (2021-2026) & (USD Million)

Table 93. Europe Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Country (2027-2032) & (USD Million)

Table 94. Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2021-2026) & (K Units)

Table 95. Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2027-2032) & (K Units)

Table 96. Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2021-2026) & (K Units)

Table 97. Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2027-2032) & (K Units)

Table 98. Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Region (2021-2026) & (K Units)

Table 99. Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Region (2027-2032) & (K Units)

Table 100. Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Region (2021-2026) & (USD Million)

Table 101. Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Region (2027-2032) & (USD Million)

Table 102. South America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2021-2026) & (K Units)

Table 103. South America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2027-2032) & (K Units)

Table 104. South America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2021-2026) & (K Units)

Table 105. South America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by

Application (2027-2032) & (K Units)

Table 106. South America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Country (2021-2026) & (K Units)

Table 107. South America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Country (2027-2032) & (K Units)

Table 108. South America Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Country (2021-2026) & (USD Million)

Table 109. South America Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Country (2027-2032) & (USD Million)

Table 110. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2021-2026) & (K Units)

Table 111. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Type (2027-2032) & (K Units)

Table 112. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2021-2026) & (K Units)

Table 113. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Application (2027-2032) & (K Units)

Table 114. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Country (2021-2026) & (K Units)

Table 115. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Quantity by Country (2027-2032) & (K Units)

Table 116. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Country (2021-2026) & (USD Million)

Table 117. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Country (2027-2032) & (USD Million)

Table 118. Dual GLP-1R/GIPR Receptor Agonist Raw Material

Table 119. Key Manufacturers of Dual GLP-1R/GIPR Receptor Agonist Raw Materials

Table 120. Dual GLP-1R/GIPR Receptor Agonist Typical Distributors

Table 121. Dual GLP-1R/GIPR Receptor Agonist Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Dual GLP-1R/GIPR Receptor Agonist Picture
- Figure 2. Global Dual GLP-1R/GIPR Receptor Agonist Revenue by Type, (USD Million), 2021 & 2025 & 2032
- Figure 3. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Type in 2025
- Figure 4. Injection Examples
- Figure 5. Oral Administration Examples
- Figure 6. Global Dual GLP-1R/GIPR Receptor Agonist Revenue by Receptor Agonist Properties, (USD Million), 2021 & 2025 & 2032
- Figure 7. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Receptor Agonist Properties in 2025
- Figure 8. Balanced Examples
- Figure 9. Biased Examples
- Figure 10. Global Dual GLP-1R/GIPR Receptor Agonist Revenue by Medicinal Efficacy, (USD Million), 2021 & 2025 & 2032
- Figure 11. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Medicinal Efficacy in 2025
- Figure 12. Long-acting Examples
- Figure 13. Short-acting Examples
- Figure 14. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
- Figure 15. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Application in 2025
- Figure 16. Diabetes Examples
- Figure 17. Obesity Examples
- Figure 18. Others Examples
- Figure 19. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value, (USD Million): 2021 & 2025 & 2032
- Figure 20. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value and Forecast (2021-2032) & (USD Million)
- Figure 21. Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity (2021-2032) & (K Units)
- Figure 22. Global Dual GLP-1R/GIPR Receptor Agonist Price (2021-2032) & (US\$/Unit)
- Figure 23. Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Manufacturer in 2025

Figure 24. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Manufacturer in 2025

Figure 25. Producer Shipments of Dual GLP-1R/GIPR Receptor Agonist by Manufacturer Sales (\$MM) and Market Share (%): 2025

Figure 26. Top 3 Dual GLP-1R/GIPR Receptor Agonist Manufacturer (Revenue) Market Share in 2025

Figure 27. Top 6 Dual GLP-1R/GIPR Receptor Agonist Manufacturer (Revenue) Market Share in 2025

Figure 28. Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Region (2021-2032)

Figure 29. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value Market Share by Region (2021-2032)

Figure 30. North America Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 31. Europe Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 32. Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 33. South America Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 34. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 35. Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Type (2021-2032)

Figure 36. Global Dual GLP-1R/GIPR Receptor Agonist Consumption Value Market Share by Type (2021-2032)

Figure 37. Global Dual GLP-1R/GIPR Receptor Agonist Average Price by Type (2021-2032) & (US\$/Unit)

Figure 38. Global Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Application (2021-2032)

Figure 39. Global Dual GLP-1R/GIPR Receptor Agonist Revenue Market Share by Application (2021-2032)

Figure 40. Global Dual GLP-1R/GIPR Receptor Agonist Average Price by Application (2021-2032) & (US\$/Unit)

Figure 41. North America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Type (2021-2032)

Figure 42. North America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Application (2021-2032)

Figure 43. North America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market

Share by Country (2021-2032)

Figure 44. North America Dual GLP-1R/GIPR Receptor Agonist Consumption Value Market Share by Country (2021-2032)

Figure 45. United States Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 46. Canada Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 47. Mexico Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 48. Europe Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Type (2021-2032)

Figure 49. Europe Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Application (2021-2032)

Figure 50. Europe Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Country (2021-2032)

Figure 51. Europe Dual GLP-1R/GIPR Receptor Agonist Consumption Value Market Share by Country (2021-2032)

Figure 52. Germany Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 53. France Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 54. United Kingdom Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 55. Russia Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 56. Italy Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 57. Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Type (2021-2032)

Figure 58. Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Application (2021-2032)

Figure 59. Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Region (2021-2032)

Figure 60. Asia-Pacific Dual GLP-1R/GIPR Receptor Agonist Consumption Value Market Share by Region (2021-2032)

Figure 61. China Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 62. Japan Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 63. South Korea Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 64. India Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 65. Southeast Asia Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 66. Australia Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 67. South America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Type (2021-2032)

Figure 68. South America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Application (2021-2032)

Figure 69. South America Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Country (2021-2032)

Figure 70. South America Dual GLP-1R/GIPR Receptor Agonist Consumption Value Market Share by Country (2021-2032)

Figure 71. Brazil Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 72. Argentina Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 73. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Type (2021-2032)

Figure 74. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Application (2021-2032)

Figure 75. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Sales Quantity Market Share by Country (2021-2032)

Figure 76. Middle East & Africa Dual GLP-1R/GIPR Receptor Agonist Consumption Value Market Share by Country (2021-2032)

Figure 77. Turkey Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 78. Egypt Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 79. Saudi Arabia Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 80. South Africa Dual GLP-1R/GIPR Receptor Agonist Consumption Value (2021-2032) & (USD Million)

Figure 81. Dual GLP-1R/GIPR Receptor Agonist Market Drivers

Figure 82. Dual GLP-1R/GIPR Receptor Agonist Market Restraints

Figure 83. Dual GLP-1R/GIPR Receptor Agonist Market Trends

Figure 84. Porters Five Forces Analysis

Figure 85. Manufacturing Cost Structure Analysis of Dual GLP-1R/GIPR Receptor Agonist in 2025

Figure 86. Manufacturing Process Analysis of Dual GLP-1R/GIPR Receptor Agonist

Figure 87. Dual GLP-1R/GIPR Receptor Agonist Industrial Chain

Figure 88. Sales Channel: Direct to End-User vs Distributors

Figure 89. Direct Channel Pros & Cons

Figure 90. Indirect Channel Pros & Cons

Figure 91. Methodology

Figure 92. Research Process and Data Source

I would like to order

Product name: Global Dual GLP-1R/GIPR Receptor Agonist Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/GF3A0C6BDD25EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF3A0C6BDD25EN.html>